The sell-side on Wall Steet is predicting Sage Therapeutics, Inc. (NASDAQ:SAGE) to grow at an accelerated rate over the next five years. Sell-side analysts are looking for the company to grow 13.80% over the next year and 13.10% over the next five years.
When deciding how to best approach the stock market, individual investors may need to figure out what their time horizon is going to be. Short-term traders may only be looking to hold stocks for a short period in order to capitalize on fluctuations. Longer-term investors may be looking at more of a buy and hold strategy, and they may not be very concerned with the day to day shifts of a stock’s price. Accumulating as much knowledge as possible about specific stocks and the markets in general can help the investor prepare for success. Because there is no magic strategy that can be employed to guarantee profits, investors may need to evaluate multiple methods before choosing which one to pursue.
Sage Therapeutics, Inc. (NASDAQ:SAGE)’s trailing 12- months EPS is -8.06. Last year, their EPS growth was -14.10% and their EPS growth over the past five years was -60.30%.
Let’s start off by taking a look at how the stock has been performing recently. Over the past twelve months, Sage Therapeutics, Inc. (NASDAQ:SAGE)’s stock was 73.32%. Last week, it was -0.79%, 9.38% over the last quarter, and 29.44% for the past half-year.
Over the past 50 days, Sage Therapeutics, Inc. stock was -3.96% off of the high and 12.74% removed from the low. Their 52-Week High and Low are noted here. -6.28% (High), 107.84%, (Low).
Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!
This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…
Sage Therapeutics, Inc. (NASDAQ:SAGE)’s performance this year to date is 73.32%. The stock has performed -0.79% over the last seven days, -2.90% over the last thirty, and 9.38% over the last three months. Over the last six months, Sage Therapeutics, Inc.’s stock has been 29.44% and 5.60% for the year.
FUTURE GROWTH ESTIMATES AND RECOMMENDATIONS
Wall Street analysts are have a consensus analyst recommendation of 1.60 on the stock. This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Brokerages covering the name have a $200.56 on the stock.
Investors may be trying to figure out how long the stock market bull run will continue. There are plenty of commentators who think that a downturn is coming soon, but there are plenty who believe that the market still has plenty of room to push higher. Preparing the portfolio for any market scenario can help ease the investor’s mind. Putting in the time to research investments as well as global economic data might help keep focus clear when things get cloudy. Closing in on the end of the year, investors may be conducting year-end portfolio reviews. Figuring out what has worked and what adjustments can be made may help iron out the wrinkles heading into the next few quarters.
The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.